Concentra (CON) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Here is how Concentra Group (CON) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Investors looking for stocks in the Medical Services sector might want to consider either Concentra Group (CON) or Medpace (MEDP). But which of these two stocks is more attractive to value investors?
The average of price targets set by Wall Street analysts indicates a potential upside of 27.1% in Concentra (CON). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Concentra (CON) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Investors interested in stocks from the Medical Services sector have probably already heard of Concentra Group (CON) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now?
The mean of analysts' price targets for Concentra (CON) points to a 30.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Concentra Group (CON) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.47 per share a year ago.
Investors interested in stocks from the Medical Services sector have probably already heard of Concentra Group (CON) and Medpace (MEDP). But which of these two companies is the best option for those looking for undervalued stocks?
CON is set to acquire Pivot Onsite Innovations, expanding its onsite occupational health services and strengthening its national footprint in workforce health solutions.
Here is how Concentra Group (CON) and Fresenius (FMS) have performed compared to their sector so far this year.
Concentra (CON) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.